BMS-986158

DRUG4 trials

Sponsors

Bristol-Myers Squibb, Dana-Farber Cancer Institute

Conditions

Advanced TumorsBrain Tumor, PediatricLymphomaMultiple MyelomaMyelofibrosisSolid Tumor, Childhood

Phase 1

Study of BMS-986158 in Subjects With Select Advanced Cancers

CompletedNCT02419417

Bristol-Myers SquibbAdvanced Tumors

Start: 2015-06-19End: 2021-03-17Updated: 2022-06-16

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

CompletedNCT03936465

Dana-Farber Cancer InstituteBrain Tumor, Pediatric, Lymphoma, Solid Tumor, Childhood

Start: 2019-09-27End: 2024-10-01Updated: 2024-10-02

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Active, not recruitingNCT04817007

Bristol-Myers SquibbMyelofibrosis

Start: 2021-03-22End: 2026-05-31Target: 216Updated: 2025-09-10

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

RecruitingNCT05372354

Bristol-Myers SquibbMultiple Myeloma

Start: 2022-10-18End: 2026-10-12Target: 260Updated: 2025-09-05

Related Papers

EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma

Blood2025-11-03

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood2024-11-058 citations

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood2023-11-026 citations

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including <i>JAK2</i> Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

Blood2023-11-02

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

HemaSphere2023-08-01

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Blood2022-11-153 citations

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial

Cancers2022-08-2339 citations

Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158

Cancer Research2020-08-152 citations

Abstract 1742: Inhibition of BET signaling leads to reversible GATA1-associated repression of hematopoietic progenitors: translation from preclinical assessment to clinical development

Cancer Research2020-08-15

Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer

Annals of Oncology2018-10-0122 citations